Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)
· seekingalpha.com
Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.
Shares of Alnylam Pharmaceuticals, Inc. ( ALNY ) have been notably weak since my last update on this biotech, falling around 18% on worries around what the fail...